Literature DB >> 28327906

European cancer mortality predictions for the year 2017, with focus on lung cancer.

M Malvezzi1,2, G Carioli1, P Bertuccio1, P Boffetta3, F Levi4, C La Vecchia1, E Negri2.   

Abstract

BACKGROUND: We predicted cancer mortality figures in the European Union (EU) for the year 2017 using most recent available data, with a focus on lung cancer.
MATERIALS AND METHODS: We retrieved cancer death certification data and population figures from the World Health Organisation and Eurostat databases. Age-standardized (world standard population) rates were computed for France, Germany, Italy, Poland, Spain, the UK and the EU overall in 1970-2012. We obtained estimates for 2017 by implementing a joinpoint regression model.
RESULTS: The predicted number of cancer deaths for 2017 in the EU is 1 373 500, compared with 1 333 400 in 2012 (+3%). Cancer mortality rates are predicted to decline in both sexes, reaching 131.8/100 000 men (-8.2% when compared with 2012) and 84.5/100 000 women (-3.6%). Mortality rates for all selected cancer sites are predicted to decline, except pancreatic cancer in both sexes and lung cancer in women. In men, pancreatic cancer rate is stable, in women it increases by 3.5%. Lung cancer mortality rate in women is predicted to rise to 14.6/100 000 in 2017 (+5.1% since 2012, corresponding to 92 300 predicted deaths), compared with 14.0/100 000 for breast cancer, corresponding to 92 600 predicted deaths. Only younger (25-44) women have favourable lung cancer trends, and rates at this age group are predicted to be similar in women (1.4/100 000) and men (1.2/100 000). In men lung cancer rates are predicted to decline by 10.7% since 2012, and falls are observed in all age groups.
CONCLUSION: European cancer mortality projections for 2017 confirm the overall downward trend in rates, with a stronger pattern in men. This is mainly due to different smoking prevalence trends in different generations of men and women. Lung cancer rates in young European women are comparable to those in men, confirming that smoking has the same impact on lung cancer in the two sexes.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Europe; cancer; lung cancer; mortality; projections; tobacco

Mesh:

Year:  2017        PMID: 28327906     DOI: 10.1093/annonc/mdx033

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  71 in total

1.  FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.

Authors:  David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

Review 2.  The efficacy and prescription of neuromuscular electrical stimulation (NMES) in adult cancer survivors: a systematic review and meta-analysis.

Authors:  Dominic O'Connor; Brian Caulfield; Olive Lennon
Journal:  Support Care Cancer       Date:  2018-07-18       Impact factor: 3.603

3.  Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Authors:  J Remon; D Isla; P Garrido; J de Castro; M Majem; N Viñolas; A Artal; E Carcereny; M R García-Campelo; P Lianes; M Provencio; O Juan; P Diz; R Blanco; R Lopez-Castro; I Maestu; C Vadell; E Felip
Journal:  Clin Transl Oncol       Date:  2017-06-28       Impact factor: 3.405

4.  Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis.

Authors:  Giuseppe Antonio Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Int J Colorectal Dis       Date:  2019-01-22       Impact factor: 2.571

5.  Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.

Authors:  Akiyoshi Kasuga; Yasuo Hamamoto; Ayano Takeuchi; Naohiro Okano; Kazuhiro Togasaki; Yu Aoki; Takeshi Suzuki; Kenta Kawasaki; Kenro Hirata; Yasutaka Sukawa; Takanori Kanai; Hiromasa Takaishi
Journal:  Invest New Drugs       Date:  2018-03-23       Impact factor: 3.850

Review 6.  The epidemiology of lung cancer.

Authors:  Patricia M de Groot; Carol C Wu; Brett W Carter; Reginald F Munden
Journal:  Transl Lung Cancer Res       Date:  2018-06

7.  Multiple primary non-breast tumors in breast cancer survivors.

Authors:  Giovanni Corso; Paolo Veronesi; Giorgia Irene Santomauro; Patrick Maisonneuve; Consuelo Morigi; Giulia Peruzzotti; Mattia Intra; Virgilio Sacchini; Viviana Galimberti
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-03       Impact factor: 4.553

8.  DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.

Authors:  Feda H Hamdan; Steven A Johnsen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-12       Impact factor: 11.205

Review 9.  Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

Authors:  Linda O'Flaherty; Harriet Wikman; Klaus Pantel
Journal:  Transl Lung Cancer Res       Date:  2017-08

10.  Lung Cancer: A Nationwide Study to Characterize Sex Differences, Incidence, and Spatial Patterns in Portugal.

Authors:  Teresa Guerreiro; Luis Antunes; Joana Bastos; Alexandra Mayer; Goncalo Forjaz; AntÓnio Araujo; Carla Nunes
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.